Business Description
Daxor Corp
NAICS : 333310
SIC : 3841
ISIN : US2394671034
Total Employee Number:
750Description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | N/A |
N/A
|
N/A
| |||
Equity-to-Asset | 1 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
Beneish M-Score | 1.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.2 | |||||
3-Year EPS without NRI Growth Rate | 23.5 | |||||
3-Year Book Growth Rate | 10.3 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.06 | |||||
9-Day RSI | 46.53 | |||||
14-Day RSI | 48.17 | |||||
3-1 Month Momentum % | -1.8 | |||||
6-1 Month Momentum % | -33.29 | |||||
12-1 Month Momentum % | -0.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.6 | |||||
Shareholder Yield % | 1.57 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Net Margin % | 88.99 | |||||
FCF Margin % | 5.54 | |||||
OCF Margin % | 5.54 | |||||
ROE % | 23.45 | |||||
ROA % | 23.2 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 6.49 | |||||
PE Ratio without NRI | 6.49 | |||||
Shiller PE Ratio | 32.27 | |||||
PEG Ratio | 0.4 | |||||
PS Ratio | 5.24 | |||||
PB Ratio | 1.17 | |||||
Price-to-Tangible-Book | 1.17 | |||||
Price-to-Free-Cash-Flow | 92.61 | |||||
Price-to-Operating-Cash-Flow | 92.61 | |||||
EV-to-Revenue | 6.06 | |||||
EV-to-Forward-Revenue | 16.98 | |||||
EV-to-FCF | 109.35 | |||||
Price-to-GF-Value | 0.29 | |||||
Price-to-Projected-FCF | 1.92 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.4 | |||||
Price-to-Graham-Number | 0.58 | |||||
FCF Yield % | 0.92 | |||||
Forward Rate of Return (Yacktman) % | 12.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DXR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Daxor Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.303 | ||
| EPS (TTM) ($) | 1.64 | ||
| Beta | 1.1264 | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.2 | ||
| Volatility % | 41.54 | ||
| 14-Day RSI | 48.17 | ||
| 14-Day ATR ($) | 0.489314 | ||
| 20-Day SMA ($) | 10.098755 | ||
| 12-1 Month Momentum % | -0.32 | ||
| 52-Week Range ($) | 8.56 - 14.7578 | ||
| Shares Outstanding (Mil) | 5.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Daxor Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Daxor Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-28 | In 45 days | ||
| General meeting for 2025 | 2026-06-23 10:30 | 9.50 (-3.75%) | ||
| Guidance call for 2026 | 2026-03-10 14:00 | 11.30 (+1.71%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 11.38 (-6.26%) | ||
| Annual report for 2025 | 2026-03-02 | 11.86 (+0.00%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-05 07:00 | 11.33 (+8.42%) | ||
| Second quarter earnings results for 2025 | 2025-08-29 | 11.28 (+4.44%) | ||
| General meeting for 2024 | 2025-06-24 10:45 | 9.46 (+0.00%) | ||
| Annual report for 2024 | 2025-03-14 | 8.16 (-4.00%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-03-06 16:30 | 7.50 (+4.86%) |
Show
Entries
Daxor Corp Frequently Asked Questions
What is Daxor Corp(DXR)'s stock price today?
The current price of DXR is $10.65. The 52 week high of DXR is $14.76 and 52 week low is $8.56.
When is next earnings date of Daxor Corp(DXR)?
The next earnings date of Daxor Corp(DXR) is 2026-08-28 Est..
Does Daxor Corp(DXR) pay dividends? If so, how much?
Daxor Corp(DXR) does not pay dividend.
Guru Commentaries on NAS:DXR
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Daxor Corp
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers